State Street’s Cardio Diagnostics CDIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.1K Buy
+10,099
New +$19.1K ﹤0.01% 4127
2025
Q2
Sell
-2,087
Closed -$20.7K 4271
2025
Q1
$20.7K Hold
2,087
﹤0.01% 4204
2024
Q4
$57.4K Buy
2,087
+637
+44% +$8.83K ﹤0.01% 4087
2024
Q3
$9.7K Hold
1,450
﹤0.01% 4263
2024
Q2
$23.9K Hold
1,450
﹤0.01% 4259
2024
Q1
$61.8K Buy
1,450
+780
+116% +$44.5K ﹤0.01% 4124
2023
Q4
$50K Hold
670
﹤0.01% 4199
2023
Q3
$6.83K Hold
670
﹤0.01% 4524
2023
Q2
$23.9K Sell
670
-720
-52% -$40.6K ﹤0.01% 4574
2023
Q1
$163K Buy
+1,390
New +$110K ﹤0.01% 4142

Other funds holding CDIO

State Street's CDIO Position: Q2 2026 in Review

State Street opened a new position in Cardio Diagnostics (CDIO) in Q2 2026: 10,099 shares worth $22.1K. The stake represents ﹤0.01% of the portfolio and ranks #4127 among its holdings. This is a return to the name: State Street previously reported a position in CDIO as recently as Q1 2025.

State Street first reported a position in CDIO in Q1 2023 and has held it in 10 quarters since. The position peaked at $163K in Q1 2023. 17 funds tracked by Wall St. Rank hold CDIO as of Q2 2026.

  • State Street held 10,099 shares of Cardio Diagnostics worth $22.1K as of Q2 2026.
  • Cardio Diagnostics was a new State Street position in Q2 2026.
  • Cardio Diagnostics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4127 holding.
  • State Street first reported a position in Cardio Diagnostics in Q1 2023 and has held it in 10 quarters since.
  • State Street's Cardio Diagnostics position peaked at $163K in Q1 2023.
  • 17 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.